Articles published by Biogen Inc.


Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
October 24, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
October 22, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB




Biogen Board Appoints Two New Independent Directors
September 12, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB


From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB


Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB







From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB



Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB



Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023
From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB

From Biogen Inc.
Via GlobeNewswire
Tickers
BIIB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.